Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
about
Nail PsoriasisCytokines and cytokine profiles in human autoimmune diseases and animal models of autoimmunityInterventions for guttate psoriasisSystemic pharmacological treatments for chronic plaque psoriasisAdverse effects of biologics: a network meta-analysis and Cochrane overviewDefinition of treatment goals for moderate to severe psoriasis: a European consensusTailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapiesKey design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an exampleTh17 Cells in Type 1 Diabetes: Role in the Pathogenesis and Regulation by Gut MicrobiomeSelective Phosphodiesterase Inhibitors for Psoriasis: Focus on ApremilastPutting together the psoriasis puzzle: an update on developing targeted therapiesManaging patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasisTreatment challenges in the management of moderate-to-severe plaque psoriasis - role of secukinumabNew Oral Therapies for Psoriasis: A Comprehensive ReviewMethotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trialsBiologic therapies in the treatment of psoriasis: a comprehensive evidence-based basic science and clinical review and a practical guide to tuberculosis monitoring.Diagnosis and management of psoriasis.Diagnostic et prise en charge du psoriasisImpact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials.Cutting Edge: Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis Vulgaris and Normalizes Skin Pathology via Concurrent Regulation of IL-17 and IL-10Randomized Placebo Control Study of Metformin in Psoriasis Patients with Metabolic Syndrome (Systemic Treatment Cohort).Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity.Efficacy of psoralen plus ultraviolet A therapy vs. biologics in moderate to severe chronic plaque psoriasis: retrospective data analysis of a patient registry.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Methotrexate vs. fumaric acid esters in moderate-to-severe chronic plaque psoriasis: data registry report on the efficacy under daily life conditions.Systemic methotrexate therapy for psoriasis: past, present and future.The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials.Efficacy of adalimumab across subgroups of patients with moderate-to-severe chronic plaque psoriasis of the hands and/or feet: post hoc analysis of REACHA costly revolution for a subgroup of patients with metastatic melanoma.Biologics in the management of psoriasis.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Update of the management of chronic psoriasis: new approaches and emerging treatment options.Psoriasis in skin of color: epidemiology, genetics, clinical presentation, and treatment nuances.The possibilities and principles of methotrexate treatment of psoriasis - the updated knowledge.The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Serum levels of TNF-α, IL-12/23p40, and IL-17 in plaque psoriasis and their correlation with disease severity.Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patientsEvidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.
P2860
Q22305813-342509DB-8349-48E5-BD31-EA31FD2CB29DQ22306446-C4DE4245-51BA-4BD4-AB08-47B7D270C6AAQ24188296-A11F4E9E-7F1D-4716-B5A4-C67A1E46449BQ24188334-2484DC86-FE05-4ED8-838A-E9635552FF95Q24234197-30391397-A57A-4C77-9E02-25BE2548B6E4Q24604445-28D18136-6192-41DA-9FCC-C5F2E9FBCAEFQ26764867-6E4C58A5-F09D-4CA1-A904-88B853246C04Q26766368-2DC489DC-2A0B-4905-9AD2-36A0C6CD1305Q26769612-45744C74-4267-4101-A68A-F19A8F4B03A1Q26781755-8BE9A791-905D-4614-9073-C6FF87B347BAQ27026785-DDBFF780-1A7E-4671-BA94-0B4DA460037BQ27693878-3EAD9432-8EAB-4777-A68A-DDBBF228E64CQ28069819-EB8115C8-D9A5-4181-93CE-765EE2155D72Q28071475-52771521-5D4D-4E24-9E7F-C04722089740Q28085725-B603204A-3434-4B8D-8F0D-0825750B9842Q30412650-93DBF697-497E-4BC9-B82A-6E545EBC79DFQ33558495-5E4C31CC-5170-4504-AB79-D4D7C4BDE3F6Q33558550-851820BB-E984-4223-B242-5685A27516A4Q33625546-4AAF2167-D4F2-47D9-8DB7-2136E085BE39Q33646955-EE3EA386-7735-462F-9078-E9C29006B1C2Q33815547-0947E01D-2EBE-4E07-A46A-6300CFD7FD18Q33841403-C0DCF845-A362-45F5-99FB-F2D08DE2FF86Q33896449-5CC3A823-CA99-4E18-95B5-59110FCF8F1AQ33939033-28EE5D5C-69A3-41FA-8496-2621E598BF81Q34112840-2416FEC9-A025-4792-A40A-C89A5B98F180Q34166896-097B760A-2AA5-4061-AD51-3E8A9FDE375DQ34294189-18E750A2-D3D3-429C-9C40-A03A93BC9CCBQ34356265-C11FC284-EB5D-47CB-BF14-9A4350004BC2Q34393068-D7402546-D8D2-490A-90C4-0A56B7914B02Q34497018-6CCEB307-59E2-4589-B5B9-1E1B0BD4C324Q34601611-82F4C330-3F33-4E1C-B591-5056B731CDABQ34620257-A35A718C-C98B-4897-B037-EFFC42455D23Q34620323-4164C909-8E7F-4EC8-834D-F27C74DFF785Q34620375-6D202FB4-782E-4DB6-8E43-DA039A3FFEFBQ34631384-212CC9C8-0CD4-4931-9179-CE1B67F5CEBEQ34945967-F69B0A58-651D-4D28-84D7-77C5A6957A7BQ34984568-538F703C-0188-43A1-A493-643420EC901EQ35155926-65BC8EA0-9BE2-4F91-940E-619C08DEBA31Q35571621-7C5CD75A-D945-4B03-AF45-6436180FCD93Q35606402-927970E6-A0EC-45D4-8E21-23D448001876
P2860
Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).
description
2007 nî lūn-bûn
@nan
2007 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@ast
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@en
Efficacy and safety results fr ...... ebo in patients with psoriasis
@nl
type
label
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@ast
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@en
Efficacy and safety results fr ...... ebo in patients with psoriasis
@nl
prefLabel
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@ast
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@en
Efficacy and safety results fr ...... ebo in patients with psoriasis
@nl
P2093
P921
P1476
Efficacy and safety results fr ...... nts with psoriasis (CHAMPION).
@en
P2093
CHAMPION Study Investigators
J-H Saurat
J-P Ortonne
K Unnebrink
L Dubertret
R G Langley
P304
P356
10.1111/J.1365-2133.2007.08315.X
P407
P577
2007-11-28T00:00:00Z